Stem Cell Transplantation: Solid Tumors

Table of Contents

Table of Contents ...................................................... 1
Related Coverage Resources ......................................... 1
Overview ..................................................................... 1
Coverage Policy ........................................................ 2
  Central Nervous System (CNS) Tumors ..................... 2
  Ewing Family of Tumors ........................................... 2
  Germ Cell Tumors ................................................... 2
  (e.g., testicular) ..................................................... 2
  Neuroblastoma ........................................................ 2
General Background ................................................. 3
  Bone .................................................................... 5
  Breast .................................................................. 6
  Central Nervous System (CNS) ............................ 6
  Germ Cell Tumors ............................................... 9
  Kidney / ............................................................. 10
  Wilms tumor ....................................................... 10
  Neuroblastoma ..................................................... 10
  Ovarian Epithelial ................................................ 11
  Retinoblastoma ................................................... 11
  Soft Tissue Sarcoma ........................................... 11
Medicare Coverage Determinations ..................... 13
Coding/Billing Information ................................. 13
References ............................................................. 14

Related Coverage Resources

Autologous Cell Therapy for Cardiac and Peripheral Arterial Disease
Chimeric Antigen Receptor T-Cell (CAR-T) and Advanced Cellular/Immune Effector Cell Therapy
Donor Lymphocyte Infusion and Hematopoietic Progenitor Cell (HPC) Boost
Stem Cell Transplantation: Blood Cancers
Stem Cell Transplantation: Non-cancer Disorders
Transplantation Donor Charges
Umbilical Cord Blood Banking

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses hematopoietic stem cell transplantation (HSCT) for adult and pediatric solid tumor cancers.
## Coverage Policy

Coverage for hematopoietic stem cell transplantation (HSCT) varies across plans. Refer to the customer’s benefit plan document for coverage details.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Hematopoietic Stem Cell Transplantation (HSCT) Coverage Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central Nervous System (CNS) Tumors</strong></td>
<td>All allogeneic transplantations must be from an appropriately-matched human leukocyte antigen (HLA) donor.</td>
</tr>
</tbody>
</table>
| **Central Nervous System (CNS) Tumors** | **Autologous HSCT is considered as medically necessary for the treatment of the following central nervous system tumors:**  
  - supratentorial primitive neuroectodermal tumor (PNET)  
  - medulloblastoma  
  - relapsed or refractory primary CNS lymphoma.  
  **Autologous HSCT is considered experimental, investigational or unproven for the treatment of ANY of the following central nervous system tumors:**  
  - anaplastic glioma  
  - astrocytoma  
  - ependymoma  
  - glioblastoma  
  - meningioma  
  - oligodendroglioma  
  - primary spinal cord tumors  
  **Allogeneic HSCT is considered experimental, investigational or unproven for the treatment of central nervous system tumors.** |
| **Ewing Family of Tumors** | **Autologous HSCT is considered medically necessary for the treatment of relapsed or progressive Ewing family of tumors.**                                                                                                           |
| **Germ Cell Tumors (e.g., testicular)** | **Single or tandem autologous HSCT is considered medically necessary for relapsed or refractory testicular and ovarian germ cell tumors.**                                                                                                             |
| **Germ Cell Tumors (e.g., testicular)** | **Up to three autologous HSCT is considered medically necessary as second-line therapy for metastatic germ cell tumors.**                                                                                                         |
| **Germ Cell Tumors (e.g., testicular)** | **EITHER of the following procedures for the treatment of testicular cancer is considered experimental, investigational or unproven:**  
  - autologous HSCT as front-line therapy  
  - allogeneic HSCT |
| **Neuroblastoma** | **Autologous HSCT is considered medically necessary for the treatment of high-risk neuroblastoma.**                                                                                                                                                                      |
| **Neuroblastoma** | **Allogeneic HSCT is considered medically necessary for the treatment of high-risk neuroblastoma when the individual is not a candidate for autologous HSCT.**                                                                                                             |
| **Neuroblastoma** | **A maximum of three tandem autologous HSCTs is considered medically necessary for the treatment of high-risk neuroblastoma.**                                                                                                                                  |
| **Retinoblastoma** | **Autologous HSCT is considered medically necessary for the treatment of retinoblastoma.**                                                                                                                                                                         |
| **Wilms Tumor** | **Autologous HSCT is considered medically necessary for the treatment of relapsed Wilms tumor.**                                                                                                                                                                          |
| **Adult - Other** | **HSCT for the treatment of ANY of the following solid tumors in an adult is considered experimental, investigational and unproven:**                                                                                                           |
Indication

Hematopoietic Stem Cell Transplantation (HSCT) Coverage Criteria

All allogeneic transplantations must be from an appropriately-matched human leukocyte antigen (HLA) donor.

- cancer of the bile duct
- cancer of the breast
- cancer of the cervix
- cancer of the colon and rectum
- cancer of the esophagus
- cancer of the gallbladder
- cancer of the lung
- cancer of the nasopharynx
- cancer of the pancreas
- cancer of the paranasal sinus
- cancer of the prostate
- cancer of the stomach (gastric cancer)
- cancer of the thymus
- cancer of the thyroid
- cancer of the uterus
- epithelial ovarian cancer
- melanoma
- renal cell carcinoma
- soft tissue sarcoma

General Background

Hematopoietic stem cell transplantation (HSCT), also called hematopoietic cell transplantation (HCT) or stem cell transplant, is a type of treatment for cancer (and a few other conditions as well). Bone marrow produces all of the different cells that make up the blood, such as red blood cells, white blood cells, and platelets. All of the cells of the immune system are also made in the bone marrow. All of these cells develop from a type of precursor cell found in the bone marrow, called a "hematopoietic stem cell." Hematopoietic stem cells are found in the peripheral blood and the bone marrow; therefore stem cells can be collected or harvested from either location.

Some of the most effective treatments for cancer, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow. After the treatment, a healthy supply of stem cells is reintroduced, or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. HSCT is a method of replacing immature blood-forming cells in the bone marrow that have been destroyed by drugs, radiation, or disease. It may be autologous (i.e., using a person's own stem cells) or allogeneic (i.e., using stem cells donated by someone else).

- Autologous transplant — In autologous transplantation, an individual's own hematopoietic stem cells are removed before the high dose chemotherapy or radiation is given, and they are then frozen for storage and later use. After chemotherapy or radiation is complete, the harvested cells are thawed and returned to the individual, like a transfusion.
- Allogeneic transplant — In allogeneic transplantation, the hematopoietic stem cells come from a donor, ideally a brother or sister with a similar genetic makeup. If an individual does not have a suitably matched sibling, an unrelated person with a similar genetic makeup may be used. Under some circumstances, a parent or child who is only half-matched can also be used; this is termed a haploidentical transplant. In other circumstances, umbilical cord blood may be used in an umbilical cord blood transplant.
- Myeloablative transplant — A myeloablative transplantation uses very high doses of chemotherapy or radiation prior to transplantation with autologous or allogeneic hematopoietic stem cells.
- Non-myeloablative transplant — A non-myeloablative transplantation, sometimes referred to as reduced intensity transplant, allows an individual to have less intensive chemotherapy before transplantation with allogeneic hematopoietic stem cells. The idea is to minimize up front toxicity by using lower doses of intensive therapy, while retaining the immune graft versus tumor effect. This approach may be
recommended for a variety of reasons including age, type of disease, other medical issues, or prior therapies.

Contraindications
Many factors affect the outcome of a tissue transplantation; the selection process is designed to obtain the best result for each individual. The presence of any significant comorbid conditions which would significantly compromise clinical care and chances of survival is a contraindication to transplant. Relative contraindications for HSCT include (but are not limited to):

- poor cardiac function (ejection fraction less than 35%)
- poor liver function (bilirubin greater than 2.0 mg/dL and transaminases greater than two times normal), unless related to disease
- poor renal function (creatinine clearance less than 50 mL/min) (not applicable for most auto transplants)
- poor pulmonary function (diffusion capacity less than 50% of predicted) human immunodeficiency virus (HIV) if not controlled or active hepatitis B, hepatitis C or human T-cell lymphotrophic virus type 1 (HTLV-1)
- Karnofsky rating less than 60% and/or Eastern Cooperative Oncology Group (ECOG) performance status greater than two

Bone Cancer
True (or primary) bone tumors start in the bone itself and may include:

- Osteosarcoma (also called osteogenic sarcoma) is the most common primary bone cancer. It starts in the bone cells. It most often occurs in young people between the ages of 10 and 30, but about 10% of osteosarcoma cases develop in people in their 60s and 70s.
- Chondrosarcoma
- Ewing tumor/Ewing sarcoma is rare in adults older than 30
- Malignant fibrous histiocytoma (MFH) most often starts in soft tissue (connective tissues such as ligaments, tendons, fat, and muscle); it’s rare in bones. This cancer is also known as pleomorphic undifferentiated sarcoma, especially when it starts in soft tissues. This cancer most often occurs in elderly and middle-aged adults. It's quite rare in children.

Central Nervous System (CNS) Tumors
Primary central nervous system (CNS) tumors are a diverse group of tumors originating in the brain or spinal cord. CNS tumors, develop from different cell types, form in different areas of the CNS. CNS tumors are more common in children than adults and constitute the most common solid tumors of childhood.

- Tumor location: The brain is divided into two compartments by the tentorium. Above the tentorium (supratentorial) are the cerebral hemispheres, basal ganglia, and the thalamus. Below the tentorium (infratentorial) are the pineal gland, the tectum, thepons, the medulla, and the cerebellum. Adult brain tumors tend to be supratentorial; however, pediatric tumors are evenly split between supratentorial and infratentorial. This division of location in the pediatric population is dependent on the age of the patient.
- Tumor type: Some CNS tumor types include astrocytoma/oligodendroglioma, anaplastic glioma/glioblastoma, adult intracranial and spinal ependymoma, adult medulloblastoma, primary spinal cord tumors, and meningiomas. Cranial primitive neuroectodermal tumors (PNET) are embryonal neoplasms showing varying degrees of differentiation. They are described by their location as infratentorial (medulloblastomas) and supratentorial (cerebral neuroblastoma, pineoblastoma, esthesioneuroblastoma).

Germ Cell Tumors (GCTs)
Germ cell tumors are growths that form from reproductive cells. Tumors may be cancerous or noncancerous. Most germ cell tumors that are cancerous occur as either cancer of the ovaries (ovarian cancer) or cancer of the testicles (testicular cancer).
• Testicular cancer: More than 90% of cancers of the testicle start in cells known as germ cells. These are the cells that make sperm. The main types of GCTs in the testicles are seminomas and non-seminomas. These types occur about equally. Seminomas tend to grow and spread more slowly than non-seminomas. Non-seminomas usually occur in men between their late teens and early 30s. Many testicular cancers contain both seminoma and non-seminoma cells.
• Ovarian: Germ cell tumors start from the cells that produce the eggs (ova). Less than 2% of ovarian cancers are germ cell tumors.

Neuroblastoma
Neuroblastoma starts in certain very early forms of nerve cells, most often found in an embryo or fetus. This type of cancer occurs most often in infants and young children. It is rare in children older than 10 years. For neuroblastoma, treatment depends on risk groups. The stage of neuroblastoma is one factor used to determine risk group. Other factors are the age of the child, tumor histology, and tumor biology.

Ovarian Cancer
The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor:
• Epithelial ovarian tumors start from the cells that cover the outer surface of the ovary. Most ovarian tumors are epithelial cell tumors. These tumors can be benign (not cancer), borderline (low malignant potential), or malignant (cancer). About 90% of malignant ovarian cancers are epithelial ovarian carcinomas.
• Germ cell tumors start from the cells that produce the eggs (ova). Less than 2% of ovarian cancers are germ cell tumors.
• Stromal tumors start from structural tissue cells that hold the ovary together and produce the female hormones estrogen and progesterone.

Some of these tumors are benign (non-cancerous) and never spread beyond the ovary. Malignant (cancerous) or borderline (low malignant potential) ovarian tumors can spread (metastasize) to other parts of the body and can be fatal.

Retinoblastoma
Retinoblastoma is a cancer that starts in the retina, the very back part of the eye. It is the most common type of eye cancer in children.

Soft Tissue Sarcoma
Bone and soft tissue sarcomas are the main two types of sarcoma. Soft tissue sarcomas can develop in soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. They can be found in any part of the body.
• Rhabdomyosarcoma is the most common type of soft tissue sarcoma seen in children.

Professional Societies/Organizations
The table below includes information and recommendations from the following sources:

1. The American Society for Transplantation and Cellular Therapy (ASTCT) (formerly known as the American Society for Blood and Marrow Transplantation [ASBMT]) Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy (Kanate, et al., 2020).

<table>
<thead>
<tr>
<th>Cancer</th>
<th>American Society for Transplantation and Cellular Therapy (2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone</td>
<td>(CR: complete response; N: Not generally recommended; C: standard of care, clinical evidence available; S: standard of care; R: standard of care, rare indication; D: developmental)</td>
</tr>
</tbody>
</table>
### NCCN GUIDELINES™ Bone cancer (v.1.2020, August 12, 2019)

**Ewing sarcoma**

High-dose therapy followed by stem cell transplant (HDT/SCT) has been evaluated in patients with localized as well as metastatic disease. HDT/SCT has been associated with potential survival benefit in patients with non-metastatic disease. However, studies that have evaluated HDT/SCT in patients with primary metastatic disease have shown conflicting results. (MS-16)

**Ewing sarcoma - Relapsed or Refractory Disease**

HDT/SCT has been associated with long-term survival in patients with relapsed or progressive Ewing sarcoma in small single-institution studies. The role of this approach is yet to be determined in prospective randomized studies. (MS-18)

**Osteosarcoma - Relapsed or Refractory Disease**

The safety and efficacy of HDT/SCT in patients with locally advanced, metastatic or relapsed osteosarcoma has been evaluated; however, efficacy in patients with high-risk disease is yet to be determined in prospective randomized studies. The optimal treatment strategy for patients with relapsed or refractory disease has yet to be defined (MS-26, MS-27).

### Breast

American Society for Transplantation and Cellular Therapy (2020)

<table>
<thead>
<tr>
<th>Adults</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer, adjuvant high risk</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Breast cancer, metastatic</td>
<td>D</td>
<td>N</td>
</tr>
</tbody>
</table>


No mention of stem cell transplant in National Cancer Institute (NCI) Breast Cancer Treatment (Adult) (PDQ®)—Health Professional Version (Updated: September 2, 2020).

### Central Nervous System (CNS)

American Society for Transplantation and Cellular Therapy (2020)

<table>
<thead>
<tr>
<th>Children (&lt;18 years)</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medulloblastoma, high risk</td>
<td>N</td>
<td>C</td>
</tr>
<tr>
<td>Other malignant brain tumors</td>
<td>N</td>
<td>C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adults</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary central nervous system Lymphoma, CR1/first partial remission</td>
<td>N</td>
<td>C</td>
</tr>
</tbody>
</table>
**Cancer**

<table>
<thead>
<tr>
<th>(consolidation)</th>
<th>N</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary central nervous system Lymphoma, Relapse, sensitive</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NCCN GUIDELINES™ Central Nervous System (CNS) Cancers (v.3.2020, September 11, 2020)**

**Adult Medulloblastoma**
- Consider collecting stem cells before craniospinal radiation (AMED-2)
- Treatment for Recurrence: High dose chemotherapy with autologous stem cell reinfusion. Footnote: Only if the patient is without evidence of disease after surgery or conventional dose re-induction chemotherapy. (AMED-3)

**Adult Medulloblastoma**
- In the setting of recurrence, several regimens are in use in the recurrence setting, most of which include etoposide. Temozolomide has also been used in this setting. High-dose chemotherapy in combination with autologous stem cell transplantation is a feasible strategy for patients who have had good response with conventional-dose chemotherapy, although long-term control is rarely achieved. (MS-23)

**Adult Medulloblastoma - Recurrence and Progression**
- High-dose chemotherapy with autologous stem cell rescue may be considered for patients showing no evidence of disease after conventional reinduction chemotherapy. (MS-24)

**Primary CNS Lymphoma**
- If complete response or complete response unconfirmed, consider high-dose chemotherapy with stem cell rescue (PCNS-2)
- Relapsed or refractory: Consider high-dose therapy with stem cell rescue (Category 2B) Footnote: If the recurrent disease goes into complete remission with reduction chemotherapy. (PCNS-3)

 Phase II trials in the United States and Europe have shown that high-dose chemotherapy with autologous stem cell transplantation following high-dose methotrexate-based chemotherapy is feasible and well-tolerated, with little evidence of neurotoxicity. (MS-25)

 There are currently no conclusive prospective data published comparing consolidation with high-dose chemotherapy regimens or high-dose chemotherapy with autologous stem cell transplantation versus maintenance therapy or observation, and there are different approaches at different institutions. Consolidation with high-dose chemotherapy and autologous stem cell transplant is frequently considered for fitter patients. (MS-26)

**PCNSL - Relapsed or Refractory Disease**
- High-dose chemotherapy with stem cell rescue may also be considered as treatment for relapsed/refractory disease in patients who did not previously receive this treatment (ie, patients who were treated with high-dose methotrexate-based therapy or with WBRT) (category 2B). Regardless of primary treatment received, stem cell rescue should only be used for relapsed/refractory disease if there is a complete or partial response to reinduction high-dose chemotherapy. (MS-30)

**NCI Childhood Astrocytoma’s Treatment (PDQ®) August 13, 2020**

 Treatment options for recurrent childhood high-grade astrocytoma’s include:
- Surgery (not considered standard treatment)
Cancer

- High-dose chemotherapy with stem cell transplant (SCT) (not considered standard treatment)
- Radiation therapy (not considered standard treatment)
- Targeted therapy with a BRAF inhibitor, for patients with a BRAF V600E mutation (not considered standard treatment)

NCI Childhood Brain Stem Glioma Treatment (PDQ®) June 8, 2020
Standard Treatment Options for Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPGs)
Standard treatment options for newly diagnosed childhood DIPGs include radiation therapy.
No chemotherapeutic (including neoadjuvant, concurrent, postradiation chemotherapy) or immunotherapy strategy, when added to radiation therapy, has led to long-term survival for children with DIPGs. This includes therapy using high-dose, marrow-ablative chemotherapy with autologous hematopoietic stem cell rescue, which has been shown to be ineffective in extending survival.

NCI Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®) October 5, 2020
Treatment of Childhood Pineoblastoma, Treatment of children aged 3 years and younger
Standard treatment options for children aged 3 years and younger with pineoblastoma include the following:
- Biopsy (for diagnosis) or subtotal resection.
- Adjuvant chemotherapy.
- High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue.

Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors
There are no standard treatment options for recurrent childhood CNS embryonal tumors. For most children, treatment is palliative, and disease control is transient in patients previously treated with radiation therapy and chemotherapy, with more than 80% of patients progressing within 2 years. For young children, predominantly those younger than 3 years at diagnosis who were never treated with radiation therapy, longer-term control with reoperation, radiation therapy, and chemotherapy is possible. Treatment approaches may include the following:
- Surgery.
- Radiation therapy.
- Chemotherapy.
- High-dose chemotherapy with stem cell rescue.
- Molecularly targeted therapy.

NCI Childhood Central Nervous System Germ Cell Tumors (GCT) Treatment (PDQ®) August 7, 2020
Treatment options for recurrent childhood CNS GCTs include the following:
- Chemotherapy followed by additional radiation therapy.
- High-dose chemotherapy with stem cell rescue with or without additional radiation therapy.

NCI Childhood Ependymoma Treatment (PDQ®) September 25, 2020
Treatment options for residual disease, no disseminated disease:
There is no evidence that high-dose chemotherapy with stem cell rescue is of any benefit.
### American Society for Transplantation and Cellular Therapy (2020)

(CR: complete response; N: Not generally recommended; C: standard of care, clinical evidence available; S: standard of care; R: standard of care, rare indication; D: developmental)

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Children (&lt;18 years)</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Allogeneic HCT</td>
<td>Autologous HCT</td>
</tr>
<tr>
<td>Germ cell tumor, relapse</td>
<td>D</td>
<td>C</td>
</tr>
<tr>
<td>Germ cell tumor, refractory</td>
<td>D</td>
<td>C</td>
</tr>
</tbody>
</table>

**NCCN GUIDELINES™ Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (v.1.2020 — March 11, 2020)**

Malignant Germ Cell Tumors

High dose chemotherapy + stem cell transplant (SCT) (category 2B)

(Category 2B). Footnote: High-dose chemotherapy regimens vary among institutions. Some patients are potentially curable with stem cell transplantation. Patients with potentially curable recurrent germ cell disease should be referred to a tertiary care institution for stem-cell transplant consultation and potentially curative therapy. (LCOC-12)

Patients achieving a complete clinical response after chemotherapy should be observed clinically every 2 to 4 months with AFP and beta-HCG levels (if initially elevated) for 2 years. For those with abnormal markers and definitive recurrent disease, options (category 2B) include: 1) high-dose chemotherapy; or 2) consider additional chemotherapy (see Principles of Systemic Therapy: Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer). Referral of these patients to a tertiary care center for stem-cell transplant consultation and potentially curative therapy is strongly recommended. Several case reports suggest that patients who have received chemotherapy for germ cell tumors may later present with growing teratoma syndrome. (MS-28)

**NCCN GUIDELINES™ Testicular Cancer (v.1.2021, November 5, 2020)**

Metastatic Germ Cell Tumors

Second-line therapy options for patients with early relapses (within 2 years of the completion of primary therapy) include enrollment in a clinical trial (preferred), conventional-dose chemotherapy, or high-dose chemotherapy. If chemotherapy is given, both conventional-dose and high-dose regimens are preferred in this setting. The conventional-dose regimens are TIP or VeIP. The high-dose regimens include high-dose carboplatin plus etoposide followed by autologous stem cell transplant, or paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide with stem cell support. (MS-20)

**NCI Childhood Central Nervous System Germ Cell Tumors (GCT) Treatment (PDQ) August 7, 2020**

Treatment options for recurrent childhood CNS GCTs include the following:

- Chemotherapy followed by additional radiation therapy.
- High-dose chemotherapy with stem cell rescue with or without additional radiation therapy

**NCI Childhood Extracranial Germ Cell Tumors Treatment (PDQ) September 24, 2020**
Cancer

Nonstandard Treatment Options for Recurrent Malignant GCTs in Children
The role of high-dose chemotherapy and hematopoietic stem cell rescue for recurrent pediatric GCTs is not established, despite anecdotal reports.

Kidney / Wilms tumor

American Society for Transplantation and Cellular Therapy (2020)
(CR: complete response; N: Not generally recommended; C: standard of care, clinical evidence available; S: standard of care; R: standard of care, rare indication; D: developmental)

<table>
<thead>
<tr>
<th>Children (&lt;18 years)</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilms tumor, relapse</td>
<td>N</td>
<td>C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adults</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal cancer, metastatic</td>
<td>D</td>
<td>N</td>
</tr>
</tbody>
</table>


NCI Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®) November 5, 2020
Treatment options for high-risk and very high-risk relapsed Wilms tumor include:
- Chemotherapy, surgery, and/or radiation therapy.
- Hematopoietic stem cell transplantation (HSCT): High-dose chemotherapy followed by autologous HSCT has been utilized for recurrent high-risk patients.

Neuroblastoma

American Society for Transplantation and Cellular Therapy (2020)
(CR: complete response; N: Not generally recommended; C: standard of care, clinical evidence available; S: standard of care; R: standard of care, rare indication; D: developmental)

<table>
<thead>
<tr>
<th>Children (&lt;18 years)</th>
<th>Allogeneic HCT</th>
<th>Autologous HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroblastoma, high risk or relapse</td>
<td>D</td>
<td>S</td>
</tr>
</tbody>
</table>

NCI Neuroblastoma Treatment (PDQ®) June 8, 2020
The treatment of neuroblastoma has evolved over the past 60 years. Generally, treatment is based on whether the tumor is low, intermediate, or high risk.

High risk: For high-risk patients, treatment has intensified to include chemotherapy, surgery, radiation therapy, myeloablative therapy and stem cell transplant (SCT), isotretinoin, and immunotherapy, resulting in survival rates of about 50%.

Treatment options for high-risk neuroblastoma typically include the following: A regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and stem cell transplant (SCT), radiation therapy, and dinutuximab with interleukin-2 (IL-2)/granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin.

Treatment options for recurrent or refractory neuroblastoma in patients initially classified as high risk include the following:
1. Chemotherapy combined with immunotherapy: Temozolomide, irinotecan, and dinutuximab.
2. 131I-MIBG. 131I-MIBG alone, in combination with other therapy, or followed by stem cell rescue.
3. ALK inhibitors. Crizotinib, or other ALK inhibitors, for patients with ALK mutations.
4. Chemotherapy:
<table>
<thead>
<tr>
<th>Cancer</th>
<th>Treatment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>Topotecan in combination with cyclophosphamide or etoposide.</td>
</tr>
<tr>
<td></td>
<td>Temozolomide with irinotecan.</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy combined with immunotherapy produces the best response rate and</td>
</tr>
<tr>
<td></td>
<td>response duration of treatments for high-risk patients with disease progression.</td>
</tr>
<tr>
<td>Ovarian Epithelial</td>
<td>NCCN GUIDELINES™ Ovarian Cancer Including Fallopian Tube Cancer and Primary</td>
</tr>
<tr>
<td></td>
<td>Peritoneal Cancer (v.1.2020 — March 11, 2020) mentions stem cell transplant under</td>
</tr>
<tr>
<td></td>
<td>Malignant Germ Cell Tumors.</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>NCI Retinoblastoma Treatment (PDQ®) September 25, 2020</td>
</tr>
<tr>
<td></td>
<td>Extraocular retinoblastoma/CNS disease treatment options include:</td>
</tr>
<tr>
<td></td>
<td>• Systemic chemotherapy and CNS-directed therapy.</td>
</tr>
<tr>
<td></td>
<td>• Systemic chemotherapy followed by myeloablative chemotherapy and stem</td>
</tr>
<tr>
<td></td>
<td>cell rescue.</td>
</tr>
<tr>
<td></td>
<td>Extraocular retinoblastoma/Synchronous trilateral retinoblastoma treatment</td>
</tr>
<tr>
<td></td>
<td>options include:</td>
</tr>
<tr>
<td></td>
<td>• Systemic chemotherapy followed by surgery and myeloablative chemotherapy with</td>
</tr>
<tr>
<td></td>
<td>stem cell rescue.</td>
</tr>
<tr>
<td></td>
<td>• Systemic chemotherapy followed by surgery and radiation therapy.</td>
</tr>
<tr>
<td></td>
<td>Extraocular retinoblastoma/Extracranial metastatic retinoblastoma treatment</td>
</tr>
<tr>
<td></td>
<td>options include:</td>
</tr>
<tr>
<td></td>
<td>• Systemic chemotherapy followed by myeloablative chemotherapy with stem</td>
</tr>
<tr>
<td></td>
<td>cell rescue and radiation therapy.</td>
</tr>
<tr>
<td>Soft Tissue Sarcoma</td>
<td>American Society for Transplantation and Cellular Therapy (2020)</td>
</tr>
<tr>
<td></td>
<td>(CR: complete response; N: Not generally recommended; C: standard of care,</td>
</tr>
<tr>
<td></td>
<td>clinical evidence available; S: standard of care; R: standard of care, rare</td>
</tr>
<tr>
<td></td>
<td>indication; D: developmental)</td>
</tr>
<tr>
<td></td>
<td>Children (&lt;18 years)</td>
</tr>
<tr>
<td></td>
<td>Allogeneic HCT</td>
</tr>
<tr>
<td></td>
<td>Autologous HCT</td>
</tr>
<tr>
<td>Soft tissue sarcoma, high</td>
<td>D</td>
</tr>
<tr>
<td>risk or relapse</td>
<td>D</td>
</tr>
</tbody>
</table>


NCI Childhood Rhabdomyosarcoma Treatment (PDQ®) August 7, 2020

Other Therapeutic Approaches
High-dose chemotherapy with autologous and allogeneic stem cell rescue has been evaluated in a limited number of patients with rhabdomyosarcoma. The use of this modality has failed to improve the outcomes of patients with newly diagnosed or recurrent rhabdomyosarcoma.

Literature Review
Omazic et al. (2016) reported an analysis of data for 61 patients with solid cancer who underwent nonmyeloablative (n=23), reduced conditioning (n=36) or myeloablative (n=2) allogeneic HSCT. Two patients received cadaveric donor grafts. Types of solid cancers included in the study were metastatic renal carcinoma.
(n=22), cholangiocarcinoma (n=17), colon carcinoma (n=15), prostate cancer (n=3), pancreatic adenocarcinoma (n=3), or breast cancer (n=1). All patients with hepatic cholangiocarcinoma and one patient with colon carcinoma (with liver metastases) underwent orthotopic liver transplantation as debulking before HSCT. Three patients with pancreatic cancer underwent Whipple surgery with radical intent. Graft failure occurred in 13 patients (21%). The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV was 47%, and that of chronic GVHD was 32%. Treatment-related mortality at two years was 21%. Five-year cancer-related mortality was 63%; eight-year survival was 12%. Risk factors for mortality were nonmyeloablative conditioning (Hazard ratio [HR] 2.95; p < .001), absence of chronic GVHD (HR, 3.57; p < .001), acute GVHD of grades II to IV (HR, 2.90; p= .002), and HLA-identical transplant (HR, 5.00; p< 0.03). Five-year overall survival rates were 15% and 9% at 10 years. Data do not suggest an enduring benefit of allogeneic HSCT for the indications included in the study.

Central Nervous System: Peer-reviewed published data are limited to small prospective case series and retrospective reviews and support the use of autologous HSCT in the treatment of supratentorial primitive neuroectodermal tumor (PNET) and medulloblastoma (Sung 2013, Fangusaro 2008, Sung 2007) as well as primary CNS lymphoma (DeFilipp, 2017; Omuro, 2015; Kasenda, 2012; Montemurro, 2007; Colombat, 2006; Soussain, 2001).

Ewing Family of Tumors: The Ewing family of tumors is a group of cancers that start in the bones or nearby soft tissues that share some common features. These tumors can develop at any age, but they are most common in the early teen years. The main types of Ewing tumors are: 1) Ewing sarcoma of bone, 2) Extraosseous Ewing tumor and 3) Peripheral primitive neuroectodermal tumor (PPNET). Several uncontrolled trials demonstrated improved or equivalent survival outcomes with autologous HSCT (Ferrari, 2011; Ladenstein, 2010).

Germ cell tumors: Several randomized controlled clinical trial data have not demonstrated improved health outcomes with the use of high-dose chemotherapy and autologous HSCT as a front-line therapy. Although data are not robust, the use of single or tandem HDC with autologous HSCT is considered an acceptable therapy for the treatment of individuals with refractory or relapsed testicular and ovarian germ cell tumors. For metastatic germ-cell tumors, three cycles of high-dose chemotherapy, each cycle followed by HSCT, is considered an appropriate second-line treatment option (Sharma, et al., 2020; Daugaard, 2011; Agawala, 2011; Lorch, 2011; Einhorn, 2007; Pico, 2005).

Neuroblastoma: For neuroblastoma, treatment depends on risk groups. The stage of neuroblastoma is one factor used to determine risk group. Other factors are the age of the child, tumor histology, and tumor biology. Autologous HSCT is a standard treatment option for individuals classified as having high-risk disease. Improved survival has been demonstrated with the use of autologous HSCT compared with chemotherapy in several randomized controlled clinical trials. Although allogeneic HSCT has not been investigated in large numbers of patients, it may play a role in treatment of those patients who are not candidates for autologous HSCT when a HLA-matched donor is available (at least 5 of 6 HLA-match) (London, 2017; Yalcin, 2015; Ladenstein, 2008).

Retinoblastoma: Retinoblastoma is a relatively uncommon tumor of childhood that arises in the retina. Several prospective case series and retrospective studies have suggested the safety and effectiveness of autologous HSCT for the treatment of retinoblastoma (Lee, 2008; Kremens, 2003). Treatment-related mortality was zero for all studies. In the study by Lee involving 14 children with bilateral disease, vision was preserved in one eye for nine patients and in both eyes doe two patients; without the use of external beam radiation. Disease-free survival (DFS) ranged from 42–107 months (de Jong, 2014; Dunkel, 2010).

Soft tissue sarcoma: A retrospective analysis investigated the value of autologous stem cell transplantation (ASCT) according to histological subtype in soft-tissue sarcoma (STS) patients who were registered in the European Society for Blood and Marrow Transplantation database between 1996 and 2016. Median progression-free (PFS) and overall survival (OS) in the entire cohort of 338 patients were 8.3 and 19.8 months, respectively, and PFS and OS at 5 years were 13% and 25%, respectively. Analysis of outcomes in different subgroups showed that younger age, better remission status before transplantation and melphalan-based preparative regimen were predictive of benefit from ASCT, whereas histology and grading had no statistically significant impact. The authors noted that their data do not allow for conclusions as to whether specific
histological subgroups benefit more from ASCT than others. Thus, the authors concluded, ASCT should not be performed in routine clinical practice (Heilig, et al., 2020).

**Wilms tumor:** Wilms tumor (also called Wilms’ tumor or nephroblastoma) is the most common type of kidney cancer in children. Results regarding benefit to event-free-survival (EFS) and overall survival (OS) are mixed; however, there are some data suggesting a survival benefit with high-dose chemotherapy and autologous HSCT for relapsed disease (Malogolowkin, 2017; Presson, 2010; Spreatanco, 2008).

**American Board of Internal Medicine’s (ABIM) Foundation Choosing Wisely® Initiative**
No relevant statements.

**Use Outside of the US**
The European Society for Medical Oncology has published numerous Clinical Practice Guidelines related to various solid tumors cancers.

### Medicare Coverage Determinations

<table>
<thead>
<tr>
<th>Contractor</th>
<th>Determination Name/Number</th>
<th>Revision Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCD</td>
<td>National STEM CELL Transplantation (Formerly 110.8.1)</td>
<td>1/27/16</td>
</tr>
<tr>
<td>LCD</td>
<td>No Local Coverage Determination found</td>
<td></td>
</tr>
</tbody>
</table>

Note: Please review the current Medicare Policy for the most up-to-date information.

### Coding/Billing Information

**Note:**
1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic</td>
</tr>
<tr>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous</td>
</tr>
<tr>
<td>38207</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td>38208</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor</td>
</tr>
<tr>
<td>38209</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor</td>
</tr>
<tr>
<td>38210</td>
<td>Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion</td>
</tr>
<tr>
<td>38211</td>
<td>Transplant preparation of hematopoietic progenitor cells; tumor cell depletion</td>
</tr>
<tr>
<td>38212</td>
<td>Transplant preparation of hematopoietic progenitor cells; red blood cell removal</td>
</tr>
<tr>
<td>38213</td>
<td>Transplant preparation of hematopoietic progenitor cells; platelet depletion</td>
</tr>
<tr>
<td>38214</td>
<td>Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion</td>
</tr>
<tr>
<td>38215</td>
<td>Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
<tr>
<td>CPT® Codes</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>38242</td>
<td>Allogeneic lymphocyte infusions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation, allogeneic</td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood derived stem-cell transplantation, allogeneic</td>
</tr>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition</td>
</tr>
</tbody>
</table>


References


3. Centers for Medicare & Medicaid Services (CMS). National Coverage Determinations (NCDs). NCD for STEM CELL Transplantation (Formerly 110.8.1) (110.23). Accessed November 2020. Available at URL address: https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=366&ncdver=1&SearchType=Advanced&CovType=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=All&KeyWord=stem+cell&KeyWordLookUp=Title&KeyWordSearchType=Exact&qk=true&bc=EAAAABAAAAA&


